Increased PRAME antigen-specific killing of malignant cell lines by low avidity CTL clones, following treatment with 5-Aza-2'-Deoxycytidine.
about
Knock-down of PRAME increases retinoic acid signaling and cytotoxic drug sensitivity of Hodgkin lymphoma cellsNYESO-1/LAGE-1s and PRAME are targets for antigen specific T cells in chondrosarcoma following treatment with 5-Aza-2-deoxycitabine.Increased PRAME-specific CTL killing of acute myeloid leukemia cells by either a novel histone deacetylase inhibitor chidamide alone or combined treatment with decitabine.Identification of Novel HLA-A*24:02-Restricted Epitope Derived from a Homeobox Protein Expressed in Hematological Malignancies.PRAME expression and promoter hypomethylation in epithelial ovarian cancer.Decitabine: a promising epi-immunotherapeutic agent in solid tumors.Oncogenic cancer/testis antigens: prime candidates for immunotherapy.Prognostic Biomarkers for Hodgkin Lymphoma.A therapeutic T cell receptor mimic antibody targets tumor-associated PRAME peptide/HLA-I antigens.Demethylating agent decitabine disrupts tumor-induced immune tolerance by depleting myeloid-derived suppressor cells.Priming of PRAME- and WT1-specific CD8(+) T cells in healthy donors but not in AML patients in complete remission: Implications for immunotherapy.In vivo immuno-targeting of an extracellular epitope of membrane bound preferentially expressed antigen in melanoma (PRAME).Elevated expression of cancer/testis antigen FSIP1 in ER-positive breast tumors.Vaccination with High-Affinity Epitopes Impairs Antitumor Efficacy by Increasing PD-1 Expression on CD8+ T Cells.
P2860
Q28486108-7203C40A-B194-4F86-827E-23AB0245523DQ34182308-6D15DDEC-E2D8-482B-89BF-08AD52D28E24Q34935239-1964DF62-F610-4CAD-A5C7-997C707B132CQ35897592-63BAC907-ECFE-4B40-8B86-7266558D7788Q37564420-7F873010-0E50-4496-8DD3-ACA4C37183CDQ38314204-D234ABA2-2672-4F8B-9CAC-B87CCE54CB7EQ38544350-8D2C5E0C-B63D-4407-AC7F-D5DDB4E55AFFQ38588503-64BD81FF-3938-4C3F-8B34-AF85132A2A15Q38719407-6C301835-1B38-4AB9-B12F-1E964DA98BA7Q38742600-B76AF28D-32BA-44FA-A415-8F3B33DD4390Q40725673-9664CA83-C68F-4C69-BF79-0E707E62711BQ42371595-8654043C-A7E3-4441-9518-20A462E6264BQ45891499-E98B59A9-C015-403F-8F67-26DB7FC0294AQ50222492-54887E36-3FD2-4D96-BDD5-2E589BAF5E12
P2860
Increased PRAME antigen-specific killing of malignant cell lines by low avidity CTL clones, following treatment with 5-Aza-2'-Deoxycytidine.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Increased PRAME antigen-specif ...... t with 5-Aza-2'-Deoxycytidine.
@en
Increased PRAME antigen-specif ...... t with 5-Aza-2'-Deoxycytidine.
@nl
type
label
Increased PRAME antigen-specif ...... t with 5-Aza-2'-Deoxycytidine.
@en
Increased PRAME antigen-specif ...... t with 5-Aza-2'-Deoxycytidine.
@nl
prefLabel
Increased PRAME antigen-specif ...... t with 5-Aza-2'-Deoxycytidine.
@en
Increased PRAME antigen-specif ...... t with 5-Aza-2'-Deoxycytidine.
@nl
P2093
P2860
P1476
Increased PRAME antigen-specif ...... t with 5-Aza-2'-Deoxycytidine.
@en
P2093
Angus Dalgleish
B Piku Basu
Edmund Poon
Fyeza Hasan
John Anderson
Mengyong Yan
Natalie Wilson
Nourredine Himoudi
Owen Williams
Rebecca Wallace
P2860
P2888
P304
P356
10.1007/S00262-011-1024-4
P577
2011-05-07T00:00:00Z